DTRMWXHS-12 is under clinical development by Zhejiang DTRM Biopharma and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DTRMWXHS-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DTRMWXHS-12 is under development for the treatment of B-cell lymphoma including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia with 17p, mantle cell lymphoma, marginal zone lymphoma (MZL), follicular B-cell non-Hodgkin's lymphoma (FL). The drug candidate is administered through oral route as a capsule. It acts by targeting Bruton's tyrosine kinase (BTK). It was also under development for the treatment of Waldenstrom's macroglobulinemia and diffuse large B-cell lymphoma.
Zhejiang DTRM Biopharma overview
Zhejiang DTRM Biopharma, a biotechnology company that manufactures pharmaceutical products. The company is headquartered in United States.
For a complete picture of DTRMWXHS-12’s drug-specific PTSR and LoA scores, buy the report here.